Renew has developed a novel enzymatic platform by synthetic biology to create a diverse pipeline of proprietary therapeutic molecules (i.e. alkylresorcinol scaffold derivatives; similar to CBGA). Uniquely, Renew’s scaffold molecules pass the blood brain barrier and engage a classic cellular receptor that controls inflammation (i.e. PPAPγ), together making this family of molecules particularly useful for indications of neuro-therapeutics. Renew is specifically focused on developing therapeutics to treat neuroinflammation pathologies, with specific focus on Traumatic Brain Injury (TBI). No drug treatment is currently approved by the FDA for TBI, while millions of patients from all age groups are effected worldwide annually. Renew’s proprietary “enzymatic chemistry” processes are in stark contrast to traditional “medicinal chemistry” processes commonly employed by Big Pharma. While traditional medicinal chemistry often requires noxious reaction components and exhibits low synthesis efficiencies, Renew’s custom engineered “enzymatic reactions” are highly efficient and scalable. These enzymatic reactions are particularly amenable for alkylresorcinol scaffold derivative molecules (that require prenylation-type synthesis). Renew’s platform for creating therapeutic derivatives by engineered enzymes is covered by a robust IP portfolio related to key enzymes (and engineered variants thereof) for production of alkylresorcinol derivatives by prenylation processes.
View Top Employees from Renew Biopharma, Inc.Website | http://www.renewbiopharma.com |
Revenue | $6 million |
Employees | 3 (3 on RocketReach) |
Founded | 2016 |
Address | 11555 Sorrento Valley Road Suite 100, San Diego, California 92121, US |
Technologies |
JavaScript,
HTML,
PHP
+12 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering, Cannabis, Community and Lifestyle, Food and Beverage, Health Care, Medical, Pharmaceutical |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 541713 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies |
Looking for a particular Renew Biopharma, Inc. employee's phone or email?
The Renew Biopharma, Inc. annual revenue was $6 million in 2024.
Ruxandra Dwinell is the Chief Counsel, Vice President of Ip of Renew Biopharma, Inc..
3 people are employed at Renew Biopharma, Inc..
Renew Biopharma, Inc. is based in San Diego, California.
The NAICS codes for Renew Biopharma, Inc. are [541, 54171, 541713, 5417, 54].
The SIC codes for Renew Biopharma, Inc. are [87, 873].